For the Inventor, By the Inventor

Enter assignee name

Zhejiang, China

Hangzhou Solipharma Co., Ltd.

USPTO Granted Patents = 19

Forward Citations = 9

Loading Chart...

Loading Chart...

14 inventors (with patents filed for the assignee):

Xiaoxia Sheng (19 out of 30 patents)

Xiaohong Sheng (17 out of 28 patents)

Tao Zhu (3 out of 7 patents)

4. Jing Wang (2 out of 8 patents)

5. Yanli Dai (2 out of 2 patents)

6. Jianfeng Zheng (2 out of 3 patents)

7. Yong Tang (2 out of 2 patents)

8. Jian Chen (1 out of 25 patents)

9. Kun Zhao (1 out of 2 patents)

10. Xiaoye Song (1 out of 3 patents)

11. Xiawei Jiang (1 out of 2 patents)

12. Xiangjun Shi (1 out of 2 patents)

13. Yinghua Shao (1 out of 1 patent)

14. Yu Dai (1 out of 1 patent)

19 patents: Sort by Forward Citations

1. 12103925 - Crystal and amorphous form of tolebrutinib, preparation method therefor, and use thereof (2024-10-01),

2. 11919906 - Crystal form of ACP-196 and method of treatment thereof (2024-03-05),

3. 11639341 - Crystal form of tipifarnib and method of treatment thereof (2023-05-02),

4. 11427528 - Fenofibrate crystalline form and manufacturing method thereof (2022-08-30),

5. 11286259 - Co-crystals of ribociclib and co-crystals of ribociclib monosuccinate, preparation method therefor, compositions thereof, and uses thereof (2022-03-29),

6. 11236077 - Fruquintinib eutectic crystal, preparation method therefor, composition, and uses thereof (2022-02-01),

7. 11236073 - ODM-201 crystalline form, preparation method therefor, and pharmaceutical composition thereof (2022-02-01),

8. 11208382 - Entinostat-containing compound, crystal form of compound thereof, and preparation method therefor and pharmaceutical composition thereof (2021-12-28),

9. 11117875 - Crystalline forms, preparation methods and pharmaceutical compositions of ozanimod (2021-09-14),

10. 11111248 - Crystal form of 2-(6-methyl-pyridin-2-yl)-3-yl-[6-amido-quinolin-4-yl]-5,6-dihydro-4H-pyrrolo[1,2-B]pyrazole, preparation method therefor and pharmaceutical composition thereof (2021-09-07),

11. 10995083 - Cocrystal of 2-(6-methyl-pyridine-2-yl)-3-yl-[6-amide-quinoline-4-yl]-5,6-dihydro-4H-pyrrole[1,2-b]pyrazole, preparation method therefor, and pharmaceutical composition (2021-05-04),

12. 10954223 - Canagliflozin monohydrate and its crystalline forms, preparation methods and uses thereof (2021-03-23),

13. 10954210 - Crystal form of tipifarnib and preparation method and pharmaceutical composition thereof (2021-03-23),

14. 10899770 - Crystal form of ACP-196 salt and preparation method, pharmaceutical composition, and use thereof (2021-01-26),

15. 10899767 - Crystal form of ACP-196, preparation method therefor and pharmaceutical composition thereof (2021-01-26),

Hangzhou Solipharma Co., Ltd. is a leading pharmaceutical company specializing in the production and distribution of high-quality drugs. With a focus on research and development, Solipharma aims to provide innovative and effective healthcare solutions to improve the lives of people worldwide. The company is committed to adopting advanced technologies and ensuring the highest standards of quality in all its products. Solipharma's diverse portfolio includes a wide range of medications for various therapeutic areas, including cardiovascular health, respiratory diseases, and infectious diseases. With a customer-centric approach, Solipharma strives to contribute to global healthcare by delivering safe, reliable, and affordable pharmaceuticals.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

19 Patents

#42 in Zhejiang

#1,373 in China

#31,708 in the World

Zhejiang, China

Hangzhou Solipharma Co., Ltd.

Forward Citations = 9

14 inventors:

Xiaoxia Sheng (19 out of 30 patents)

Xiaohong Sheng (17 out of 28 patents)

Tao Zhu (3 out of 7 patents)

4. Jing Wang (2 out of 8 patents)

5. Yanli Dai (2 out of 2 patents)

Please report any incorrect information to support@idiyas.com

Loading…